EVGN: financial statements from SEC — TradeAlmanac

EVGN

Evogene Ltd.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	4m	6m	3m	2m
Cost of revenue	4m	2m	1m	909,000
Gross profit	−241,000	3m	1m	766,000
Research and development	8m	13m	16m	21m
Selling, general and administrative	4m	7m	5m	6m
Operating income	−14m	−19m	−22m	−27m
Pre-tax income	−13m	−15m	−22m	−30m
Income tax	1,000	9,000	19,000	90,000
Net income	−8m	−18m	−26m	−30m
Earnings per share	1.08	−2.90	−5.20	−6.44
Earnings per share, diluted	1.08	−2.90	−5.20	−6.44
Weighted average shares	8m	6m	5m	4m

Balance sheet

Metric	Aug 18, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash and equivalents	—	13m	15m	21m	29m	32m	—
Receivables	—	317,000	1m	357,000

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating cash flow	−14m	−20m	−22m	−24m
Depreciation and amortisation	1m	1m	1m	2m
Share-based compensation	654,000	1m	1m	1m
Capital expenditure

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)